Results 31 to 40 of about 31,863 (238)
Precision medicine offers the opportunity to improve the benefit–risk profile of new therapies by prospectively identifying patients most likely to respond or least likely to experience harm; however, its systematic integration into drug development remains inconsistent outside oncology.
Ingrid Holst‐Laubjerg +1 more
wiley +1 more source
Dear Editor, I wish to report that the first gene therapy procedure in Italy for the treatment of severe or moderately severe hemophilia B has been successfully administered at the Policlinico of Milan....
Pier Mannuccio Mannucci
doaj +1 more source
Septal Release: A Targeted Surgical Strategy for Recurrent Epistaxis
ABSTRACT Background Recurrent epistaxis is a common pediatric condition that is typically managed with conservative therapies, but a subset of patients require surgical intervention after treatment failure. We seek to describe the efficacy of septal release for refractory pediatric epistaxis patients. Objective To compare outcomes of septal release for
Alexandra Welschmeyer +6 more
wiley +1 more source
Report on the diagnosis and treatment of hemophilia in China (Version 2024)
Hemophilia is a hemorrhagic disease caused by a lack of clotting factors due to genetic mutations, and is a representative of rare diseases. The prevalence rate of hemophilia is about 2.73/100,000–3.09/100,000 in China, and the absolute number of ...
Feng Xue +11 more
doaj +1 more source
Abstract Objective This study explores the barriers to the use of tranexamic acid (TXA) for the management of postpartum hemorrhage (PPH) and provides recommendations to improve its use. Methods We conducted a mixed‐methods assessment involving 229 healthcare professionals in Kano, Lagos, and Niger States of Nigeria.
Chukwunonso Nwaokorie +5 more
wiley +1 more source
Emicizumab Associated Rhabdomyolysis in Hemophilia A
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation.
Joseph A. Wilson +5 more
doaj +1 more source
Porcine model of hemophilia A. [PDF]
Hemophilia A is a common X chromosome-linked genetic bleeding disorder caused by abnormalities in the coagulation factor VIII gene (F8). Hemophilia A patients suffer from a bleeding diathesis, such as life-threatening bleeding in the brain and harmful ...
Yuji Kashiwakura +15 more
doaj +1 more source
ABSTRACT This study explores how social capital and chronic illness self‐management influence career development competency among young people with chronic disabling health conditions (YPCDHC) in Hong Kong. Using data from 485 participants aged 15–29, path analysis showed that school/workplace social capital had the strongest positive effects on career
Steven Sek‐yum Ngai +10 more
wiley +1 more source
Abstract Purpose To compare the 2‐year incidence of (1) revision due to periprosthetic joint infection (PJI) and (2) all‐cause revision after primary knee arthroplasty (KA) in patients with/without obesity and to compare the microbial profiles in early (≤ 90 days) and late (91–730 days) PJI.
Saber M. Aljuboori +4 more
wiley +1 more source
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA
The development of neutralizing antibodies in hemophilia is a serious complication of factor replacement therapy. These antibodies, also known as “inhibitors”, significantly increase morbidity within the hemophilia population and lower the quality of ...
Davide Matino +2 more
doaj +1 more source

